Smiths Detection Inks MDx License with Novartis | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Smiths Detection and Novartis Diagnostics have signed a license and collaboration agreement to develop and commercialize Smiths Detection's Bio-Seeq PCR-based instrument and infectious disease diagnostic tests.

Smiths will develop and enhance the Bio-Seeq platform for use in a range of point-of-care diagnostic tests that Novartis Diagnostics will then move through clinical trials, regulatory affairs, and sales and marketing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.